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Objectives: Decision on treatment of systemic sclerosis (SSc) related interstitial lung disease
(ILD) largely relies on the findings on high resolution computed tomography (HRCT) and there
is a need for improvement in assessment of the fibrotic activity. The objectives of this study
were to study biomarkers in bronchoalveolar lavage fluid (BALF) from SSc patients with ILD
and to relate the findings to the severity and activity of lung fibrosis.
Methods: Fifteen patients with early SSc and 12 healthy controls were subjected to BAL. Cell
counts and analyses of CXCL5, CXCL8 and S100A8/A9 were performed in BALF and serum. COMP
and KL-6 were measured in serum. HRCT of lungs was quantified for ground glass opacities
(GGO), reticulation and traction bronchiectases.
Results: BALF concentrations of CXCL8 (p < 0.001), CXCL5 (p Z 0.002) and S100A8/A9
(p Z 0.016) were higher in patients than controls. Serum KL-6 (p < 0.001) was increased in
SSc patients and correlated with BALF concentration of eosinophils (rSZ 0.57, pZ 0.027). Pa-
tients with more widespread GGO on HRCT were characterised in BALF by a higher eosinophil6 171620; fax: þ 46 46 128468.
@med.lu.se (R. Hesselstrand).
3 Elsevier Ltd. All rights reserved.
3.03.015
1080 R. Hesselstrand et al.count (p Z 0.002) and in serum by higher KL-6 (p Z 0.008). Patients with more fibrosis were
characterised in BALF by higher eosinophil count (p Z 0.014), higher CXCL8 (p Z 0.005) and
S100A8A/A9 (p Z 0.014) concentration and in serum by a higher serum COMP (p Z 0.023).
Conclusions: In SSc related ILD, biomarkers from BALF and serum correlate to findings on HRCT
suggesting usefulness as markers of presence and extent of lung fibrosis.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Systemic sclerosis (SSc, scleroderma) is characterised by
fibrosis in skin and internal organs, progressive vascular
obliteration and the production of autoantibodies.1 Pul-
monary complications have been recognised as the leading
cause of death in SSc.2,3 The identification of interstitial
lung disease (ILD), often developed early on in the disease,
has been facilitated by the widespread usage of high res-
olution computed tomography (HRCT) of the lungs. Identi-
fication and characterisation of activity in ILD is however
very uncertain. Furthermore, it is still debated which pa-
tients might benefit from any possible therapy since reli-
able markers of severity are lacking.
HRCT can identify patients with SSc and ILD with a poor
prognosis.4 However, the prognostic value of bronchoalveolar
lavage (BAL) cellular profiles in SSc associated ILD is still
unclear.5e7 Analyses of soluble biomarkers in BAL fluid (BALF)
might provide prognostic information. BALF analysis does also
offer the possibility to study local disease mechanisms.8
Radiological characterisation of ILD in SSc is usually
consisted of the two major forms usual interstitial pneu-
monia (UIP) and nonspecific interstitial pneumonia (NSIP),
the latter being the most common. In NSIP the prognosis
worsens in the presence of eosinophilia in BALF.9 Eosinophil
count in BALF was associated with decreased diffusion ca-
pacity for carbon monoxide (DLCO)
7 and some SSc patients
display eosinophilia in peripheral blood.10 Patients with
idiopathic pulmonary fibrosis (IPF) have a negative corre-
lation between both the absolute numbers and percentage
of eosinophils in BALF and survival,11 and biopsy studies of
IPF and pulmonary fibrosis related to collagen vascular
diseases show a correlation between eosinophil concen-
trations in peripheral blood and in lung tissue.12 Increased
levels of eosinophils may be seen in lung tissue from pa-
tients with ILD, especially in IPF and hypersensitivity
pneumonitis and also to a lesser degree in SSc.13
CXCL5, also known as epithelial derived neutrophil acti-
vating peptide 78 or ENA-78, is a chemokine produced by
epithelial cells following stimulation by interleukin-1 or
tumour necrosis factor-alpha. It is also expressed in eosino-
phils, which supports the notion that eosinophils are not just
mere targets for chemokines, but also have immunoregula-
tory properties.14 In patients with exacerbation of asthma,
endobronchial biopsies have shown increased number of
CXCL5 expressing cells and a relation between CXCL5 and the
number of eosinophils.15 CXCL5 has been explored in ILD,
where it has been found to be elevated in BALF from patients
with IPF compared to healthy controls.16
CXCL8, also known as interleukin-8 or IL-8, is a chemo-
kine often produced by macrophages and epithelial cells. Itis a mediator of inflammatory response and an angiogenic
factor.17 Hypoxia may result in accumulation of inflamma-
tory cells and structural changes featured by fibrosis in the
tissue surrounding the area of low oxygen. In cultured fi-
broblasts CXCL8 and CCL11 were both increased following
hypoxic stimulation.18 Hypoxia can also increase the levels
of procollagen in the supernatant from cultured fibro-
blasts,18 and CXCL8 is higher in BALF from patients with ILD
than in healthy controls.16 In SSc associated ILD CXCL8
levels from BALF have been found to be elevated19,20
although one study found CXCL8 to be overexpressed only
in vitro.21
The S100A8/A9 heterodimer is also referred to as calpro-
tectin,MRP8/14 or calgranulinA andB. It is considered tobe a
damage associated molecular pattern molecule and as such,
an activator of the innate immune system via Toll-like re-
ceptor 4. In SSc, faecal level of S100A8/A9 has been explored
as a possible biomarker of gastrointestinal disease.22 In IPF,
increased levels of themonomer S100A9 have been identified
in BALF.23,24 The level of S100A9 in BALF has also been pro-
posed to be a possible biomarker of fibrosis in IPF.25
Cartilage oligomeric matrix protein (COMP or
thrombospondin-5) is a large disulfide-linked pentameric
glycoprotein discovered and characterised in cartilage.26 It
has gained increasing attention in SSc as a biomarker for
activity in skin fibrosis and to a lesser extent in ILD.27,28
Krebs von den Lungen-6, or simply KL-6, is a glycoprotein
antigen expressed mainly on type II pneumocytes in alveoli
and respiratory bronchiolar epithelial cells. The serum level
of KL-6 correlates to the presence of ILD and is also related
to activity of ILD in SSc.29
There is a need for improvement in assessment of the
fibrotic activity in ILD. Based on our previous work on
immunological and fibrotic effects of S100A8/A9 and COMP
we wanted to explore the relationship to other biomarkers
known to be associated with neutrophil and eosinophil
activation. Thus, the aim of this study was to analyse CXCL5,
CXCL8 and S100A8/A9 in the circulation and in BALF from SSc
patients with ILD and to relate the findings to the severity of
ILD using imaging, and activity of ILD, using cellular profile in
BALF and measurement of COMP and KL-6 in serum.Patients & methods
Patients
We included 15 previously untreated SSc patients with short
disease duration (Table 1) and signs of ILD on HRCT of the
lungs. They underwent examination with BAL before initi-
ation of treatment and 5 patients also had a second BAL
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in conjunction with the BAL. For comparison 12 healthy
non-smoking controls (6 males and 6 females) were exam-
ined with BAL, and another 12 healthy non-smoking controls
(4 males and 8 females) were used for comparison of serum
markers. The study was approved by the regional ethics
committee. A written informed consent was obtained from
all subjects before they were entered into the study in
accordance with the Declaration of Helsinki.
After BAL 13 out of the 15 SSc patients were treated with
immunosuppressive therapy (5 with azathioprine, 8 with
cyclophosphamide). Six patients were treated with oral
prednisolone at the time of BAL. Their daily dose was
2.5 mg in one case, 5 mg in 3 cases and 10 mg in 2 cases.
Four of the 5 patients who also underwent a second BAL
were treated with oral prednisolone at a stable dose.
The patients fulfilled the 1980 ACR criteria for SSc30 and
the disease was classified as diffuse cutaneous SSc (dcSSc)
or limited cutaneous SSc (lcSSc) depending on the extent of
skin involvement.1 Skin involvement was determined by the
modified Rodnan skin score (mRss).31 The disease onset was
defined as the first non Raynaud’s manifestation.Table 1 Baseline demographics of 15 SSc patients.
Median (25the75th percentile)
or n
Age (years) 57 (49e68)
Disease duration (years) 1.0 (0.5e1.0)
Male/female 6/9
lcSSc/dcSSc 8/7
mRSS 9 (3e19)
VC (p%) 73.0 (63.0e95.0)
DLCO (p%) 61.0 (39.0e69.0)
lcSSc: limited cutaneous systemic sclerosis; dcSSc: diffuse
cutaneous systemic sclerosis; mRSS: modified Rodnan skin
score.Methods
All HRCT images were analysed by the same chest radiolo-
gist (GB), who was blinded concerning clinical details
except diagnosis. Each patient was analysed for the extent
of ground glass opacities (GGO) and reticulations (esti-
mated in % of the total lung volume with a minimum step
size of 5%). Fibrosis was defined by the presence of traction
bronchiectases within areas of GGO and reticulation.32 The
extent of traction bronchiectases was described and staged
as 0 Z non detectable, 1 Z few (1e5), 2 Z intermediary
(6e10) and 3Z extensive (>10). The spatial distribution of
pulmonary involvement was defined as number of involved
regions on HRCT (min 0; max 6). The scans were split into
six regions, three for each lung: above carina; between
pulmonary venous confluence and carina; and below pul-
monary venous confluence, as reported previously.33
Pulmonary function tests included measurement of vital
capacity (VC) by flow-volume spirometry and DLCO by
single-breath test (using Jaeger GmbH, Wu¨rzburg, Ger-
many). The DLCO value used was corrected for calculated
alveolar volume.
Anti centromeric antibodies (ACA) were analysed by in-
direct immunofluorescence technique using the human
Hep-2 cell line as substrate and anti topoisomerase I anti-
bodies (ATA) by immunodiffusion test.
BAL was performed in a subsegmental bronchus of the
right middle lobe by installation of 100e150 ml of buffered
saline divided into 3e4 aliquots. The volume of the recov-
ered lavage fluid varied between 26 and 70 ml. Differential
cell counts from BALF were performed on cytospin prepa-
rations and stained with the MayeGru¨newaldeGiemsa. In
total, 400 cells were counted by the same person (MW).
Analyses of CXCL5, CXCL8, S100A8/A9, KL-6 and COMP
were done in duplicates. Human CXCL8 was assayed with
DuoSet ELISA (R&D Systems, Minneapolis, MN, USA), human
CXCL5 was assayed with Quantikine ELISA (R&D Systems,
Minneapolis, MN, USA) following the manufacturer’sinstructions. The detection limits for the assays are 7.5 pg/
ml for CXCL8, and 15 pg/ml for CXCL5. S100A8/A9 was
measured by a commercially available ELISA-kit (Bu¨hlmann
Laboratories, Scho¨nenbuch, Switzerland). Dilution and
spiking experiments showed the ELISA to be reliable also in
BALF. KL-6 in serum was measured with sandwich enzyme
immunoassay (EIA) according to the manufacturer’s in-
structions (EIDIA Co., Ltd., Tokyo, Japan), the detection
limit is 26 U/ml. Serum COMP was measured with a com-
mercial sandwich ELISA using two monoclonal antibodies
directed against separate antigenic determinants on the
human COMP molecule (AnaMar, Lund, Sweden). The
detection limit is 0.1 U/l and the intra- and interassay co-
efficient of variation is <5%. The upper limit of normal for
serum COMP is 15 U/l.Statistics
Data are presented as median (25the75th percentile). As-
sociations between variables were analysed using Spear-
man’s correlation. Comparisons between groups were done
with the ManneWhitney U test and between first and sec-
ond assessment by Wilcoxon rank test. A p-value <0.05 was
considered significant.Results
Description
The demographic description of patients is presented in
Table 1. Median age for patients was 57 years whereas the
BALF controls were slightly younger (p Z 0.04) with me-
dian age (25the75th percentile) of 42.5 (27e52) years.
The serum controls had a median age (25the75th
percentile) of 54 (47e65) years. One patient was positive
for ACA and 4 for ATA. Baseline HRCT showed median
(25the75th percentile) GGO of 20 (10e30)% and reticula-
tion of 10 (0e10)%. Two patients had no detectable trac-
tion bronchiectases, 5 had few, 7 intermediary and one
extensive. Two patients had 2 involved regions on HRCT, 3
patients had 4 involved regions and 10 patients
had involvement of all 6 regions. Only one patient was a
current smoker.
Table 2 Correlation between measurements within BALF
in SSc at baseline.
BALF CXCL8 CXCL5 S100A8/A9
BALF rS (p)
CXCL8 0.68 (0.005) 0.81 (0.001)
CXCL5 0.68 (0.005) 0.62 (0.013)
S100A8/A9 0.81 (<0.001) 0.62 (0.013)
Lymphocytes 0.43 (0.11) 0.53 (0.044) 0.47 (0.077)
Neutrophils 0.63 (0.012) 0.40 (0.14) 0.74 (0.002)
Eosinophils 0.60 (0.017) 0.49 (0.066) 0.40 (0.14)
Macrophages 0.81 (<0.001) 0.63 (0.012) 0.85 (0.001)
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As expected SSc patients had higher concentrations of
neutrophils and eosinophils in their BALF compared to
healthy controls whereas lymphocytes or macrophages
were not increased (Figure 1A). Cytokine analyses showed
increased concentrations of CXCL8, CXCL5 and S100A8/A9
in BALF from patients whereas only KL-6 was increased in
serum from SSc patients (Figure 1A and B).
Correlations between BAL and serum
measurements in SSc at baseline
Serum KL-6 correlated with BALF concentration of eosino-
phils (rS:0.57; p Z 0.027) and serum-CXCL5 correlated
negatively with BALF concentration of S100A8/A9 (rS:
0.74; p Z 0.003).
Within BALF examinations of SSc patients CXCL8 corre-
lated with CXCL5, S100A8/A9, neutrophil count, and
eosinophil count, CXCL5 correlated with CXCL8, S100A8/A9,
lymphocyte count and S100A8/A9 correlated to CXCL8,
CXCL5 and neutrophil count. Despite normal concentra-
tions, macrophage count correlated negatively with CXCL8,
CXCL5 and S100A8/A9 (Table 2).
At the time of the first BAL, oral dose of prednisolone
correlated with CXCL5 concentration in BALF (rS Z 0.64,
p Z 0.011), and S100A8/A9 in serum (rS Z 0.80,Figure 1 Comparison between patients and controls assessed by
the picture and units within brackets.pZ 0.001), but not to cell count in BALF, CXCL8 or S100A8/
A9 in BALF or COMP or KL-6 in serum (data not shown).
Longitudinal BALF findings
Five SSc patients underwent a follow-up BAL after 1 year.
Four of them were treated with azathioprine and one with
cyclophosphamide. VC had improved by 10% and serum
levels of CXCL5 had decreased significantly (Figure 2A and
B). It is, however, important to note that BALF concentra-
tions of cells and soluble biomarkers were unaltered
despite treatment.(A) BALF or (B) serum measurements. p-values are depicted in
Figure 2 First and the second assessment of 5 SSc patients who were subjected to BAL at diagnosis and after one year of
immunosuppressive treatment for SSc related ILD. p-values are depicted in the picture and units within brackets.
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In patients, BALF concentration of eosinophils correlated
with mRSS (rS Z 0.64, p Z 0.009) and inversely with the
DLCO at baseline (rSZ 0.58, pZ 0.025) and at follow-up
(rS Z 0.59, p Z 0.034). BALF concentrations ofTable 3A Comparison between SSc patients with limited or ext
10% GGO
n 6
Median (25the75th perce
VC (p%) 85.5 (71.25e106.25)
DLCO (p%) 63.5 (60.0e70.5)
BALF
Lymphocytes (106/l) 7.75 (3.75e8.25)
Neutrophils (106/l) 2.25 (0.0e14.25)
Eosinophils (106/l) 0.50 (0.0e1.25)
Macrophages (106/l) 82.0 (63.4e93.4)
CXCL8 (pg/ml) 51.4 (35.8e313)
CXCL5 (pg/ml) 33.3 (14.8e148)
S100A8/A9 (mg/ml) 0.0510 (0.0295e5.27)
Serum
COMP (U/l) 10.9 (8.98e18.0)
KL-6 (U/ml) 362 (306e796)eosinophils did not correlate with baseline or follow-up
VC, or change in VC or DLCO (data not shown). None of
the other cells or soluble biomarkers, measured in BALF
or serum, correlated with baseline or follow-up
VC, baseline or follow-up DLCO, change in VC or DLCO or
mRSS.ensive ground glass opacities on HRCT.
>10% GGO p
9
ntile)
69.0 (59.0e84.0) 0.087
49.0 (32.0e71.5) 0.14
9.0 (7.0e14.2) 0.11
6.0 (4.5e21.2) 0.14
4.0 (3.5e5.0) 0.002
57.0 (46.5e78.5) 0.098
262 (67.5e349) 0.077
155 (24.3e326) 0.31
1.95 (0.516e3.94) 0.34
15.6 (12.0e17.8) 0.29
916 (786e1978) 0.008
Table 3B Comparison between SSc patients with limited or extensive fibrosis on HRCT.
Limiteda Extensivea p
n 7 8
Median (25the75th percentile)
VC (p%) 93.0 (73.0e106) 66.0 (57.5e72.25) 0.024
DLCO (p%) 62.0 (61.0e69.0) 44.0 (32.0e69.5) 0.064
BALF
Lymphocytes (106/l) 7.5 (5.0e9.0) 8.75 (7.25e12.75) 0.20
Neutrophils (106/l) 3.5 (0.0e5.0) 8.0 (4.5e25.88) 0.081
Eosinophils (106/l) 0.5 (0.0e3.5) 4.0 (2.38e5.0) 0.014
Macrophages (106/l) 83.5 (75.0e92.5) 57.0 (39.8e72.6) 0.024
CXCL8 (pg/ml) 53.3 (35.8e83.4) 300 (117e533) 0.005
CXCL5 (pg/ml) 19.8 (1.8e64.8) 159 (33.3e349) 0.12
S100A8/A9 (mg/ml) 0.0510 (0.0280e0.155) 3.23 (1.38e4.60) 0.014
Serum
COMP (U/l) 11.1 (9.0e15.0) 15.6 (13.35e20.78) 0.023
KL-6 (U/ml) 636 (316e1275) 854 (715e1803) 0.23
a Limited fibrosis: <10% reticulation or <6 traction bronchiectases. Extensive fibrosis: 10% or more reticulation and >5 traction
bronchiectases.
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Quantification of ILD was done on HRCT. Patients with more
widespread GGO on HRCT were characterised in BALF by a
higher eosinophil count and in serum by higher KL-6 (Table
3A). Patients with more fibrosis defined as more numerous
traction bronchiectases and more widespread reticulation
were characterised in BALF by higher eosinophil count,
lower macrophage count and higher CXCL8 concentration
and in serum by a higher serum COMP (Table 3B).Discussion
This exploratory study shows that concentrations of CXCL5,
CXCL8 and S100A8/A9 are increased in BALF from early SSc
patients with ILD compared to healthy controls. These in-
flammatory markers are highly related to the cellular pro-
files of BALF where cell count of eosinophils gives us the
most valuable information. However, this does not neces-
sarily mean that soluble biomarkers can replace cell
counting per se. In addition, many pathophysiologicaly
relevant cells present in the tissue are hardly represented
at all in BALF where the procedure involves sampling cells
already present in the airway lumen. Examples are
mesenchymal cells such as mast cells, dendritic cells and
fibroblasts, which rarely are present in BALF, but frequently
seen in tissue biopsies. In contrast, soluble mediators are
believed to reflect not only cellular inflammation in the
airway lumen, but also active or passive diffusion, reflect-
ing the tissue inflammation.
The correlation between BALF measurements of CXCL5,
CXCL8 and S100A8/A9 and BALF concentrations of lym-
phocytes, neutrophils and eosinophils indicate that they
are involved in the disease process. However, none of them
seem to be more specific in ILD related to SSc, and their
clinical value remains to be elucidated. Five patients were
subjected to a second BAL. Neither soluble biomarkers norcell count changed during one year of immunosuppressive
treatment. Although it is possible to explain this finding by
a type 2 error it is also highly possible that one year of
immunosuppressive treatment is insufficient to diminish the
immune activation in the lung. This is in keeping with the
findings of Silver et al. who found abnormal follow-up BAL-
findings in all patients with abnormalities at baseline.34
This rather modest response to therapy may also explain
why the patients treated with cyclophosphamide in the
scleroderma lung study improved the first year, when they
were subjected to therapy, but deteriorated again during
the second year of follow-up when, in most cases, no
therapy was given.35,36 Thus, a longer period of treatment
could prove to be advantageous. A lower number of mac-
rophages were found in those with evidence of more active
disease. One probable explanation could be that active
macrophages are more adherent to the surface of the air-
ways and thus less prone to be sampled by BAL. This is
supported by previous studies showing an increased frac-
tion of activated macrophages and macrophage associated
biomarkers in BALF.37
In this study, serum concentration of KL-6 was also
increased in patients, in contrast to CXCL5, CXCL8, S100A8/
A9 andCOMP thatwere not. The usefulness of serumKL-6 as a
biomarker for activity in ILD has previously been shown.29
The relation between serum KL-6 and BALF eosinophil con-
centration is of interest since BALF eosinophils have been
associated with a worse prognosis.7 The lack of correlation
between serum COMPand BALF analyses can be explained by
the fact that serum COMP in SSc originates either from the
normal physiological turn over, or, in early dcSSc cases froma
pathologic influx from the skin fibrosis which may obscure
the influx of COMP from the lungs.28
It is possible to speculate on why biomarkers from serum
and BALF correlated differently to HRCT findings. The dif-
ferences in GGO, reticulation and traction bronchiectases
could be a result of the natural temporal evolution where the
patients pass through different phases of disease at different
Biomarkers from bronchoalveolar lavage fluid 1085pace, or the differences in HRCT pattern represent different
phenotypes. Some evidence point in the direction of a tem-
poral evolution. KL-6 is known as a marker of disease activity
and was increased in patients compared to controls and was
higher in patients withmore extensive GGO. It was, however,
not higher in patients with more extensive reticulation or
with more traction bronchiectases. Although the notion of
GGO to represent activity in fibrosis, so called alveolitis, has
beenabandoned in favour of different causes ofGGO, it is still
possible that GGO in this study represent early fibrosis,
whereas reticulation represents slightly more well estab-
lished fibrosis. In that case KL-6 is higher during a period of
fibrotic activity whereas there is no difference in KL-6
depending on the amount of damage. Higher BALF concen-
trations of CXCL8, S100A8/A9 and eosinophils in patientswith
more extensive reticulation and more traction bronchiecta-
ses may on the other hand be regarded as a sign of severity
rather than activity.
Limitations of the present study are the small number of
patients, the use of one single radiologist and a scoring sys-
tem less commonly used. However, our scoring system
correlated to VC and seems appropriate in the present study.
In addition, the use of BALF solely from the right middle lobe
may not always be representative since there may be inter-
lobular variations in BALF cellularity, although by using the
same lobe, the variability in recovery will be less.
In conclusion we have found a correlation between sol-
uble biomarkers and cell counts in BALF from early SSc
patients. Cell count and measurement of soluble bio-
markers are still increased despite one year of immuno-
suppressive treatment. Biomarkers from BALF and serum
correlate to findings on HRCT, but larger and longitudinal
studies are required to determine the usefulness.
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